AstraZeneca also "follow" the first three altogether

2013 was an important year for AstraZeneca's transformation, with the announcement of a strategic reorganization that would focus the company on three areas, one of

In 2013, MedImmune, AstraZeneca's global biopharmaceutical R&D arm, spent $440 million to acquire Spirogen and began to venture into ADC

The cooperation with the First Sangong in 2019 truly opened the star road

Now it seems that I have to sigh at the viciousness

Follow the first three altogether

The success of DS-8201 also quickly ushered in the development of ADC drugs in the DXd class

Through the skilled fast follow strategy, Hengrui Pharmaceutical has rapidly developed a number of DXd series ADC drugs, and laid out multiple targets

In addition to relying on the ADC drugs provided by the first triad, AstraZeneca also began to seek internal independent research and development, and followed the technical route

At this year's AACR meeting, AstraZeneca also disclosed its preclinical results

The oncology business has grown to become one of AstraZeneca's

References:

DS-8201 is not the end point: the development of camptothecin and its derivatives ADC and strategies to enhance therapeutic effect

Global market capitalization TOP10 pharmaceutical companies - AstraZeneca R&D pipeline combing

Fighting HER-2 again, BYTEC's new generation of HER-2 ADC was approved clinically

DS8201 was approved for the third cancer species, HER2+NSCLC

Fighting HER-2 again, BYTEC's new generation of HER-2 ADC was approved clinically

Hengrui "heavy position" ADC